Research and Markets: U.S. Preclinical Animal Imaging Systems Market 2010

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/b1d800/u_s_preclinical_a) has announced the addition of Frost & Sullivan's new report "U.S. Preclinical Animal Imaging Systems Market" to their offering.

This research service analyzes the characteristics of the U.S. Preclinical Animal Imaging Systems Market since 2006. It examines the markets segmentation, technologies, key market metrics and penetration level, key influential growth factors (drivers, restraints, challenges, broad market trends), the markets competitive landscape (i.e., competitors, products, and end-users), . Based on these characteristics, annual unit shipments, unit pricing, revenues and installed base metrics are estimated and forecasted for each market segment through the year 2016, and the key factors affecting each forecast are examined. Competitor market shares are also estimated for the year of 2009.

This research service titled U.S. Preclinical Animal Imaging Systems Market provides important trends, measurements, and analyses of key modalities used in preclinical imaging. In this research, Frost & Sullivan's expert analysts thoroughly examine the following technologies: preclinical optical imaging systems, preclinical nuclear systems (micro-positron emission tomography (PET), micro-PET/computed tomography (CT), micro-single photon emission computed tomography (SPECT), micro-SPECT/CT, tri-modality), preclinical CT systems (micro-CT), preclinical magnetic resonance imaging (MRI) systems and preclinical high-frequency ultrasound (HF-US)} systems.

Market Overview:

Improved Product Capabilities of Preclinical Animal Imaging Systems Hold them in Good Stead despite a Shortage of Funding

The preclinical animal imaging systems market has bounced back from the consolidation in the pharmaceuticals and biotechnology industries, limited grant funding, and shortage in the supply of medical isotopes by enhancing its product capabilities. In addition, the markets evolving competitive landscape and the increasing acceptance of imaging as a standard in preclinical animal research are expected to bolster it till 2016. Product improvements have included simplification of system operability, higher potential for clinical translation, and, in some cases, significantly lower purchase and ownership costs. Meanwhile, the markets landscape is shifting with existing competitors expanding into multiple market segments and vendors with game-changing product offerings entering the fray. One of the most influential growth factors is the introduction of innovative imaging systems that decrease the costs and complexity of preclinical imaging, says the analyst of this research. Such imaging systems are broadening the range of potential end-users in the market.

These considerable product advancements notwithstanding, end users are deterred by the systems high purchase costs. Besides, there are also the costs associated with owning and operating traditional, advanced imaging equipment such as preclinical MRI systems. The auxiliary expenses of owning a preclinical imaging device include dedicated site construction, hiring of a specialized technician, and system maintenance. Moreover, the substantial downsizing and consolidation in the pharmaceuticals and biotechnology industries over the last couple of years have compelled potential customers to tighten their purse strings and substantially reduce preclinical research budgets. Relatively low-cost, easy-to-use, and easy-to-site preclinical imaging systems capable of providing adequate performance in the vast majority of new and existing preclinical imaging applications are becoming more widely available, notes the analyst. However, further market penetration may not be easily achievable until the pharmaceuticals and biotechnology industries stabilize and are able to budget the capital necessary to acquire one or more preclinical imaging systems.

Market participants have to provide quantitative proof of the cost, time, and credibility benefits of imaging in research for drug and medical technology development. Equally important are their abilities to cater to the varying price needs and application pursuits of customers in both the industry and non-industry customer segments of this market. They can hope to achieve deeper market penetration by demonstrating to pharmaceutical and biotechnology companies the ways in which imaging can ultimately lower their costs and improve success rates. To make the most of market opportunities, vendors should make available many different imaging modalities, at as many different price tiers as possible. This variety in product offerings and price points will help them reach out to the broadest range of customers.

Market Sectors:

Expert analysts thoroughly examine the following market sectors in this research: